CA2450787C - Active ingredient combination for pharmacological addictive substance or intoxicant therapy - Google Patents

Active ingredient combination for pharmacological addictive substance or intoxicant therapy Download PDF

Info

Publication number
CA2450787C
CA2450787C CA002450787A CA2450787A CA2450787C CA 2450787 C CA2450787 C CA 2450787C CA 002450787 A CA002450787 A CA 002450787A CA 2450787 A CA2450787 A CA 2450787A CA 2450787 C CA2450787 C CA 2450787C
Authority
CA
Canada
Prior art keywords
pharmacologically acceptable
derivatives
active ingredient
acceptable salts
single dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002450787A
Other languages
English (en)
French (fr)
Other versions
CA2450787A1 (en
Inventor
Joachim Moormann
Hermann Mucke
Klaus Opitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HF Arzneimittelforschung GmbH and Co KG
Original Assignee
HF Arzneimittelforschung GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HF Arzneimittelforschung GmbH and Co KG filed Critical HF Arzneimittelforschung GmbH and Co KG
Publication of CA2450787A1 publication Critical patent/CA2450787A1/en
Application granted granted Critical
Publication of CA2450787C publication Critical patent/CA2450787C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
CA002450787A 2001-06-18 2002-06-15 Active ingredient combination for pharmacological addictive substance or intoxicant therapy Expired - Fee Related CA2450787C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10129265A DE10129265A1 (de) 2001-06-18 2001-06-18 Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
DE10129265.1 2001-06-18
PCT/EP2002/006630 WO2002102388A2 (de) 2001-06-18 2002-06-15 Wirkstoffkombination von z.b. galanthamin oder desoxypeganin mit z.b. acamprosat oder memantin gegen sucht wie z.b. alkoholismus

Publications (2)

Publication Number Publication Date
CA2450787A1 CA2450787A1 (en) 2002-12-27
CA2450787C true CA2450787C (en) 2009-06-02

Family

ID=7688529

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002450787A Expired - Fee Related CA2450787C (en) 2001-06-18 2002-06-15 Active ingredient combination for pharmacological addictive substance or intoxicant therapy

Country Status (27)

Country Link
US (1) US20040192683A1 (enExample)
EP (1) EP1397138B1 (enExample)
JP (1) JP2005500298A (enExample)
KR (1) KR20040010744A (enExample)
CN (1) CN1527711A (enExample)
AR (1) AR034493A1 (enExample)
AT (1) ATE286397T1 (enExample)
AU (1) AU2002323873B2 (enExample)
BR (1) BR0211008A (enExample)
CA (1) CA2450787C (enExample)
CZ (1) CZ299951B6 (enExample)
DE (2) DE10129265A1 (enExample)
EA (1) EA006647B1 (enExample)
ES (1) ES2236551T3 (enExample)
HU (1) HUP0400865A3 (enExample)
IL (2) IL159345A0 (enExample)
MX (1) MXPA03011825A (enExample)
MY (1) MY129726A (enExample)
NO (1) NO20035458D0 (enExample)
NZ (1) NZ529944A (enExample)
PL (1) PL367207A1 (enExample)
PT (1) PT1397138E (enExample)
SK (1) SK287180B6 (enExample)
TW (1) TWI325320B (enExample)
UA (1) UA76753C2 (enExample)
WO (1) WO2002102388A2 (enExample)
ZA (1) ZA200309232B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
DE10318714B4 (de) * 2003-04-25 2006-03-23 Hf Arzneimittelforschung Gmbh Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE102004048927A1 (de) * 2004-10-06 2006-04-20 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Kombination enthaltend Desoxypeganin und Cyp2D6 Inhibitoren
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
AU2006244297A1 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of CNS disorders
WO2006124584A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow
DE602006017719D1 (de) 2005-09-01 2010-12-02 Mitsubishi Chem Corp Verfahren zur wärmebehandlung von polyesterteilchen und verfahren zur mehrstufigen festphasenpolykondensation von polyesterteilchen
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
US9463172B2 (en) 2009-02-12 2016-10-11 Indiana University Research & Technology Corporation Material and methods for treating developmental disorders including comorbid and idiopathic autism
EP3132793A1 (en) 2009-12-02 2017-02-22 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9000046B2 (en) 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
RS65198B1 (sr) * 2010-12-03 2024-03-29 Nalpropion Pharmaceuticals Llc Povećana biodostupnost leka u terapiji naltreksonom
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
TWI678202B (zh) * 2016-12-14 2019-12-01 陸汝斌 組合物用於製備治療酒癮或酒精濫用之藥物的用途
WO2019040748A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE
BG67408B1 (bg) * 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
DE3843239C1 (enExample) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CZ295528B6 (cs) * 1994-10-21 2005-08-17 Sanochemia Pharmazeutika Ag Způsob výroby derivátů 4a,5,9,10,11,12-hexahydro-6H-benzofuro[3a,3,2-ef][2]benzazepinu
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
WO1999054280A1 (en) * 1998-04-17 1999-10-28 Kenneth Curry Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus

Also Published As

Publication number Publication date
WO2002102388A2 (de) 2002-12-27
EP1397138B1 (de) 2005-01-05
PL367207A1 (en) 2005-02-21
ATE286397T1 (de) 2005-01-15
NO20035458D0 (no) 2003-12-08
HK1063292A1 (en) 2004-12-24
DE10129265A1 (de) 2003-01-02
CZ20033390A3 (en) 2004-03-17
EP1397138A2 (de) 2004-03-17
MY129726A (en) 2007-04-30
CZ299951B6 (cs) 2009-01-07
UA76753C2 (uk) 2006-09-15
AR034493A1 (es) 2004-02-25
BR0211008A (pt) 2004-10-26
JP2005500298A (ja) 2005-01-06
SK287180B6 (sk) 2010-02-08
CA2450787A1 (en) 2002-12-27
WO2002102388A3 (de) 2003-09-18
ZA200309232B (en) 2004-07-21
IL159345A0 (en) 2004-06-01
KR20040010744A (ko) 2004-01-31
MXPA03011825A (es) 2005-03-07
EA200400041A1 (ru) 2004-04-29
EA006647B1 (ru) 2006-02-24
HUP0400865A3 (en) 2011-03-28
HUP0400865A2 (hu) 2004-07-28
IL159345A (en) 2009-02-11
SK15652003A3 (sk) 2004-04-06
CN1527711A (zh) 2004-09-08
PT1397138E (pt) 2005-04-29
ES2236551T3 (es) 2005-07-16
DE50201958D1 (de) 2005-02-10
TWI325320B (en) 2010-06-01
US20040192683A1 (en) 2004-09-30
AU2002323873B2 (en) 2006-11-16
NZ529944A (en) 2007-02-23

Similar Documents

Publication Publication Date Title
CA2450787C (en) Active ingredient combination for pharmacological addictive substance or intoxicant therapy
CN102695502B (zh) 用于治疗药瘾和改善药瘾相关行为的组合物
JP2009517393A (ja) 不安症の治療方法
ZA200404053B (en) Use of desoxypeganine for treating clinical depression.
WO1998005208A1 (en) Method for treating substance abuse
AU2002354856B2 (en) Active substance combination for medicamentous therapy of nicotine dependency
US20060199866A1 (en) Combination of desoxypeganine and mecamylanine for the treatment of alcohol abuse
NZ529005A (en) Use of desoxypeganine for the treatment of pathological manifestations of the central nervous system based on intoxication with psychotrophic substances
HK1063292B (en) Active ingredient combination (e.g. galanthamine or desoxypeganine with acamprosate or memantine) for treating a dependence on addictive substances or narcotics
HK1209058B (en) Compositions for treating drug addiction and improving addiction-related behavior
HK1176285B (en) Compositions for treating drug addiction and improving addiction-related behavior

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed